

INFLAMMATORY BOWEL DISEASE

Trichuris suis therapy in Crohn's disease

R W Summers, D E Elliott, J F Urban Jr, R Thompson, J V Weinstock

Gut 2005;54:87–90. doi: 10.1136/gut.2004.041749

See end of article for authors' affiliations

Correspondence to:
Dr R W Summers, James A Clifton Center for Digestive Diseases, Department of Internal Medicine, University of Iowa Roy J and Lucille A Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242, USA; robert-summers@uiowa.edu

Revised version received 28 March 2004
Accepted for publication 9 April 2004

Background: Crohn's disease is common in highly industrialised Western countries where helminths are rare and uncommon in less developed areas of the world where most people carry worms. Helminths diminish immune responsiveness in naturally colonised humans and reduce inflammation in experimental colitis. Thus exposure to helminths may help prevent or even ameliorate Crohn's disease.

Aims: The aim of the study was to determine the safety and possible efficacy of the intestinal helminth *Trichuris suis* in the treatment of patients with active Crohn's disease.

Patients: Twenty nine patients with active Crohn's disease, defined by a Crohn's disease activity index (CDAI) ≥ 220 were enrolled in this open label study.

Methods: All patients ingested 2500 live *T suis* ova every three weeks for 24 weeks, and disease activity was monitored by CDAI. Remission was defined as a decrease in CDAI to less than 150 while a response was defined as a decrease in CDAI of greater than 100.

Results: At week 24, 23 patients (79.3%) responded (decrease in CDAI > 100 points or CDAI < 150) and 21/29 (72.4%) remitted (CDAI < 150). Mean CDAI of responders decreased 177.1 points below baseline. Analysis at week 12 yielded similar results. There were no adverse events.

Conclusions: This new therapy may offer a unique, safe, and efficacious alternative for Crohn's disease management. These findings also support the premise that natural exposure to helminths such as *T suis* affords protection from immunological diseases like Crohn's disease.

Crohn's disease is a chronic relapsing inflammatory reaction that may affect any part of the gastrointestinal tract. It is common in parts of the world where helminthic colonisation is rare and uncommon in those areas where most people carry worms.¹ It appears to result from an inappropriate immune response to normal gut flora. Helminths down-modulate the host immune response to unrelated antigens,^{2–4} a property that could be beneficial in Crohn's disease. Helminths reduce inflammation in experimental murine colitis.^{1 5–7} *Trichuris suis*, the porcine whipworm, is similar to human whipworm *T trichiura*. Ingestion of *T suis* ova results in short term self limited colonisation of humans.⁸ We therefore conducted a 24 week clinical trial to evaluate the safety and possible efficacy of live *T suis* therapy in Crohn's disease.

METHODS

Patients were enrolled in a 24 week open label study after giving informed consent. The University of Iowa Institutional Review Board approved the protocol. Subjects with Crohn's disease, as defined by standard clinical, radiological, and histological criteria, were recruited and followed at the University of Iowa and clinical practices in the State of Iowa. Patients 18–72 years old were eligible if they had a Crohn's disease activity index (CDAI) between 220 and 450.⁹ A small bowel series and colonoscopy were required within the year before enrolment. Patients continued their Crohn's disease medications if they met the following enrolment criteria: (1) mesalamine or derivatives if they had been receiving it for > 8 weeks and the same dose for > 4 weeks; (2) oral prednisone up to 25 mg/day if patients had been receiving it for > 8 weeks and the same dose for > 4 weeks; and (3) azathioprine or 6-mercaptopurine (6-MP) if patients had been receiving it for > 6 months and the same dose for > 8 weeks. Before enrolment, patients had to have a haemoglobin concentration of > 10.0 g/dl, white blood count of 5000 – $15\ 000$ /mm³, platelet count $> 150\ 000$ /mm³, no iron or vitamin B₁₂ deficiency, total bilirubin < 1.5 mg/dl, aspartate

aminotransferase and alanine aminotransferase < 100 U/dl, alkaline phosphatase < 250 U/dl, blood urea nitrogen < 40 mg/dl, serum creatinine < 2.0 mg/dl, and stool examination negative for pathogens or *Clostridium difficile* toxin. Women had a negative pregnancy test and practised birth control. Patients with ileostomy, colostomy, resection > 50 cm, obstructive symptoms, or anticipated need for surgery were excluded. They were not enrolled if (1) treatment in the last 12 weeks included cyclosporine, methotrexate, infliximab, or other immunomodulatory agents, (2) treatment in the last two weeks included antibiotics, antifungal, or antiparasitic medications, and (3) they had other diseases that could interfere with compliance or interpretation of the results.

Specific pathogen free pigs were given *T suis* ova by gastric gavage. After allowing time for worm maturation, adult worms were isolated from the colon and cultured in vitro. Ova produced in vitro were collected and allowed to embryonate for 5–6 weeks in phosphate buffered saline containing penicillin/streptomycin/amphotericin B at 22°C. The embryonated ova were then made bacteria free using 0.2% K₂Cr₂O₇, washed with sterile saline, and stored at 5°C in phosphate buffered saline. Standard viral and bacterial cultures were performed on aliquots of ova to assure that they contained no pathogens. Pigs were inoculated with stored ova at regular time intervals to assure that the ova remained infective. This analysis demonstrated that stored ova retained viability for at least nine months. Eggs were divided into individual aliquots of 2500. This number of ova was the same as that used in our earlier pilot study.¹⁰ Subjects returned every three weeks to drink the ova suspended in a commercial drink. The study coordinator witnessed that all of the subjects consumed the drink.

Abbreviations: CDAI, Crohn's disease activity index; 6-MP, 6-mercaptopurine; DNBS, dinitrobenzene sulphonic acid; TNBS, trinitrobenzene sulphonic acid

Table 1 Baseline characteristics of the patients*

Variable	No of patients (n = 29)
Sex (M/F)	13/16 (44.8% M)
Mean age (y)	34.0 (10.8)
Smoking status (yes/total)	9/29 (31%)
Initial CDAI	296.7 (46.9)
Median duration of disease (y)	4 (1.5–8)
Site of disease	
Small bowel only	10/29 (34.5%)
Colon only	5/29 (17.2%)
Small bowel and colon	14/29 (48.3%)
Ileal resection	5/29 (17.2%)
Medications at entry	
No medications	5/29 (17.2%)
Mesalamine	10/29 (34.5%)
Corticosteroid	3/29 (10.3%)
Azathioprine	3/29 (10.3%)
Mesalamine+corticosteroid	1/29 (3.4%)
Mesalamine+azathioprine/6-MP	1/29 (3.4%)
Corticosteroid+azathioprine/6-MP	3/29 (10.3%)
Mesalamine+corticosteroid+azathioprine/6-MP	3/29 (10.3%)

CDAI, Crohn's disease activity index; 6-MP, 6-mercaptopurine.

Patients kept daily diaries of clinical symptoms. Dosing of all other inflammatory bowel disease medications was held constant. The following were obtained at entry and every six weeks: medical history and physical examination, pregnancy test, complete blood count, liver profile, and stool examination for ova, pathogens, and *C difficile* toxin. Means (SD) are given. Medians are presented with interquartile range. The two tailed Fisher's exact test was used to examine patient characteristics that might predict response or remission.

RESULTS

A total of 29 patients were enrolled and their baseline characteristics are shown in table 1. Most patients had longstanding disease (median 3.9 (1.5–6.8) years) and were refractory to standard inflammatory bowel disease therapy before enrolment. Fourteen patients were on corticosteroids and/or azathioprine/6-MP. Only 5/29 (17%) were on no medications; of these, 10 previously had tried corticosteroids and/or other immunosuppressants (azathioprine, 6-MP, infliximab). Mean CDAI was 294, indicating that patients were moderately ill. The cohort included patients with anatomical disease distribution similar to that of the Crohn's disease population at large.

Patients were compliant with the protocol; all patients completed their symptom diaries, attended all clinic visits, and received all doses of the ova. None was lost to follow up. Four withdrew at or before week 12 because of ongoing disease activity, and one withdrew between weeks 12 and 24 because of pregnancy. Ongoing disease activity was defined as failure to respond or achieve remission and these individuals are included in the analysis. There was no indication that the ova therapy made any patient more ill, and there were no side effects or complications attributable to therapy. Patients developed no new symptoms such as nausea, vomiting, abdominal pain, or worsening of diarrhoea. There was no deterioration in CDAI in the four patients that withdrew before week 12. Analysis of laboratory data collected during the study showed no significant changes in complete blood count or differential, blood urea nitrogen or creatinine, or aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase. All stool specimens were negative for ova and parasites.

At week 12, 22 patients (75.9%) responded (decrease in CDAI >100 points or CDAI <150) and 19/29 (65.5%) were in remission (CDAI <150). At week 24, 23 patients (79.3%) experienced a response and 21/29 (72.4%) were in remission




Figure 1 (A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (B) Mean change in Crohn's disease activity index (CDAI, mean (SD)) for responders to ova therapy. CDAI <150 is remission. $p < 0.0001$, week 12 or week 24 compared with baseline (time 0).

(fig 1A). Mean initial CDAI of responders was 287.1 (47.8). It decreased to 92.0 (49.2) at week 12 and 99.9 (35.6) at week 24 (fig 1B). Thus the mean improvement in CDAI for these patients was 195.1 and 187.2 at weeks 12 and 24, respectively. There were six patients with a baseline CDAI between 250 and the minimum entry criterion of 220. All six achieved both a response (improvement in CDAI of >100) and remission (CDAI <150).

We performed subset analysis of patient characteristics looking for predictors of outcomes. Sex, patient age, disease duration, smoking status, or disease location did not influence the frequency of response or remission. There was a trend for patients using immunosuppressive drugs to improve to a greater degree than those not using these agents (table 2). Also, patients with a prior history of terminal ileum resection were less responsive.

DISCUSSION

Human helminthic parasites were considered as a therapeutic option. Many could not be used because there are no available sources other than a human carrier. Eggs from such a source would risk inadvertent transmission of pathogenic microbial agents. Also, some human helminths have disease potential or raise public health concerns.

Trichuris species are helminths with favourable characteristics for therapeutic use. Their life cycle minimises the risk of inadvertent colonisation. *Trichuris* ova mature in the soil and are ingested by the host. Ova hatch in the duodenum, releasing larvae that ultimately grow in 6–8 weeks into adult worms. They migrate to the terminal ileum and colon but do not invade the host. Worms can remain viable for 1–2 years in the natural host. Adult worms release ova that are shed into the stool. These ova are immature and are not capable of colonising another host until they incubate in the soil for several weeks to allow embryonation.

We chose *T suis* as the helminth to colonise subjects in this study. *T suis*, the porcine whipworm, is genetically related to *T trichiura*, the human whipworm. *T suis* is not a natural human parasite but it has been shown experimentally to colonise humans briefly without causing disease.⁸ The ova can be produced using pathogen free pigs, and processed to assure absence of biological contaminants.

Treatment with *T suis* ova for 24 weeks yielded a response rate of nearly 80% and a remission rate of nearly 73%, which was much greater than the anticipated placebo effect.^{11–14} This was particularly notable as many patients had refractory disease. Thus *T suis* ova therapy may produce substantial and sustained improvement in active Crohn's disease. However,

Table 2 Subset analysis of patient characteristics for response and remission

Group	Total No	12 weeks Response		12 weeks Remission		24 weeks Response		24 weeks Remission	
		No	%	No	%	No	%	No	%
Sex									
Male	12	9	75.00	8	66.67	10	83.33	8	66.67
Female	17	13	76.47	11	64.71	13	76.47	13	76.47
p value			1.000		1.000		1.000		0.683
Patient age									
<32 y	14	12	85.71	11	78.57	12	85.71	11	78.57
≥32 y	15	10	66.67	8	53.33	11	73.33	10	66.67
p value			0.390		0.245		0.651		0.682
Disease duration									
<3.9 years	14	12	85.71	11	78.57	12	85.71	12	85.71
≥3.9 y	15	10	66.67	8	53.33	11	73.33	9	60.00
p value			0.390		0.245		0.651		0.215
Current smoking status									
Non-smoker	20	15	75.00	13	65.00	16	80.00	15	75.00
Smoker	9	7	77.78	6	66.67	7	77.78	6	66.67
p value			1.000		1.000		1.000		0.675
Disease location									
Small bowel only	14	11	78.57	10	71.43	11	78.57	10	71.43
Small bowel and colon	8	5	62.50	5	62.50	6	75.00	6	75.00
Colon only	7	6	85.71	4	57.14	6	85.71	5	71.43
p value			0.547		0.792		0.874		0.982
Ileal resection									
Resection	5	2	40.00	2	40.00	2	40.00	2	40.00
No resection	24	20	83.33	17	70.83	21	87.50	19	79.17
p value			0.075		0.306		0.046		0.112
Use of immunosuppressives*									
Not using	15	9	60.00	9	60.00	9	60.00	9	60.00
Currently using	14	13	92.86	10	71.43	14	100.00	12	85.71
p value			0.080		0.700		0.017		0.215

*Immunosuppressives = corticosteroids, azathioprine, or 6-mercaptopurine.

the study was open label, and we cannot exclude a high placebo effect. The treatment caused no side effects or complications even in patients receiving multiple immunosuppressants (for example, corticosteroids and azathioprine/6-MP), suggesting a high safety profile.

Subset analysis of the data suggested that patients on immunosuppressive therapy fared better, as did patients with an intact terminal ileum. We can only speculate on the reason for these observations. It is possible that immunosuppressives could have influenced *T suis* colonisation. Also, there could have been a synergistic interaction between the immunomodulatory effect of the helminths and the immunosuppressive effect of the other drugs. Terminal ileal resection also could have affected worm colonisation, or perhaps residual symptoms from the surgery confounded CDAI scoring. Both of these observations need confirmation in a prospective trial to assure that they were not artefacts.

There is an immunological basis to expect that exposure to helminths such as *T suis* will prove beneficial in Crohn's disease. Crohn's disease involves over reactive Th1 pathways, and helminths blunt Th1 responses. For example, helminths attenuate intestinal inflammation in animal models of inflammatory bowel disease. Interleukin 10 deficient mice spontaneously develop a Th1-type colitis characterised by infiltration of the lamina propria with interferon γ producing CD4+ T cells.¹⁵ Colonisation with *T muris* or *Heligmosomides polygyrus* retards development of colitis in interleukin 10 deficient mice.¹ Mice and rats treated with di- or trinitrobenzene sulphonic acid (DNBS, TNBS) develop a Th1 cytokine driven colitis that shares features with Crohn's disease.¹⁶ Mice and rats exposed to *Schistosoma mansoni* are resistant to TNBS colitis.^{6,7} Colonisation of mice with *Trichinella spiralis* diminishes DNBS induced colitis.⁵ This protection is associated with decreased systemic and colonic interferon γ and interleukin 12 expression, which are critically important Th1 cytokines.

Colonisation with helminths augments several immunoregulatory pathways that limit Th1-type inflammation. Helminths induce production of interleukin 4 and interleukin 13, which are Th2 cytokines. This Th2 response inhibits production of Th1 cytokines thereby reducing colitis severity.⁶ Helminths also induce regulatory T cells and immune regulatory substances such as transforming growth factor β , interleukin 10, and prostaglandin E₂ that assist in maintaining host mucosal homeostasis.⁴

In summary, *T suis* is well tolerated and appears efficacious for Crohn's disease in this open label trial. Helminths probably inhibit intestinal inflammation by mechanisms different from current medications. Helminths may offer an easy to administer alternative or supplement to currently available therapeutic agents. These results justify a double blind controlled clinical trial. Furthermore, these results support the hypothesis that helminthic exposure provides protection against some immune mediated inflammatory disease like Crohn's disease.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge the support of Betty Musgrave, clinical research coordinator. Drs Miriam B Zimmerman and William Clarke, Department of Biostatistics provided assistance with study design, statistical methods, and data analysis. Additional participating University of Iowa gastroenterologists included Drs Jeffrey Field, Khurram Qadir, and David Ramkumar. Collaborating gastroenterologists from the State of Iowa included: Drs Dean Abramson, Nile Dusdieker, Joseph Ewing, Jon Gibson, Bernard Leman, Randall Lengeling, Sudhakar Misra, James Piro, Douglas Purdy, Leon Qiao, Surish Reddy, Robert Silber, Joseph Truszkowski, and Gary Weinman.

The Crohn's and Colitis Foundation of America provided the primary support for this study. The Broad Medical Research Program of the Eli and Edythe L Broad Foundation, the Ed and Liliane Schneider Family Foundation, and the Thomas Irwin Memorial Fund also provided partial support. The study sponsors had no involvement in the study design, collection, analysis, and interpretation of the

data, in the writing of the report; or in the decision to submit the paper for publication.

Authors' affiliations

R W Summers, D E Elliott, R Thompson, J V Weinstock, James A Clifton Center for Digestive Diseases, Department of Internal Medicine, University of Iowa Roy J and Lucille Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA

J F Urban Jr, Nutrient Requirements and Functions Laboratory, Beltsville Human Nutrition Research Center, Agricultural Research Service, United States Department of Agriculture, Beltsville, Maryland, USA

Conflict of interest: None declared.

REFERENCES

- 1 **Elliott DE**, Urban JF Jr, Argo CK, *et al*. Does the failure to acquire helminthic parasites predispose to Crohn's disease? *FASEB J* 2000;**14**:1848–55.
- 2 **Sabin EA**, Araujo MI, Carvalho EM, *et al*. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with *Schistosoma mansoni*. *J Infect Dis* 1996;**173**:269–72.
- 3 **Borkow G**, Leng Q, Weisman Z, *et al*. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and energy. *J Clin Invest* 2000;**106**:1053–60.
- 4 **Weinstock JV**, Summers R, Elliott DE. Helminths and harmony. *Gut* 2004;**53**:7–9.
- 5 **Khan WI**, Blennerhasset PA, Varghese AK, *et al*. Intestinal nematode infection ameliorates experimental colitis in mice. *Infect Immun* 2002;**70**:5931–7.
- 6 **Elliott DE**, Li J, Blum A, *et al*. Exposure to schistosome eggs protects mice from TNBS colitis. *Am J Physiol* 2003;**284**:G385–91.
- 7 **Moreels TG**, Nieuwendijk RJ, De Man JG, *et al*. Concurrent infection with *Schistosoma mansoni* attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats. *Gut* 2004;**53**:99–107.
- 8 **Beer RJ**. The relationship between *Trichuris trichiura* (Linnaeus 1758) of man and *Trichuris suis* (Schrank 1788) of the pig. *Res Vet Sci* 1976;**20**:47–54.
- 9 **Best WR**, Bechtel JM, Singleton JW, *et al*. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 1976;**70**:439–44.
- 10 **Summers RW**, Elliott DE, Qadir K, *et al*. *Trichuris suis* seems to be safe and possibly effective in the treatment of inflammatory bowel disease. *Am J Gastroenterol* 2003;**98**:2034–41.
- 11 **Sands BE**, Winston BD, Salzberg B, *et al*. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. *Aliment Pharm Ther* 2002;**16**:399–406.
- 12 **Sandborn WJ**, Feagan BG, Hanauer SB, *et al*. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. *Gastroenterology* 2001;**120**:1330–8.
- 13 **Panaccione R**, Canadian Consensus Group on the use of infliximab in Crohn's disease. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. *Can J Gastroenterol* 2001;**15**:371–5.
- 14 **Feagan B**. Infliximab in the treatment of Crohn's disease. *Can J Gastroenterol* 2000;**14**(suppl C):6C.
- 15 **Berg DJ**, Davidson N, Kuhn R, *et al*. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. *J Clin Invest* 1996;**98**:1010–20.
- 16 **Neurath MF**, Fuss I, Kelsall BL, *et al*. Antibodies to interleukin 12 abrogate established experimental colitis in mice. *J Exp Med* 1995;**182**:1281–90.

EDITOR'S QUIZ: GI SNAPSHOT

Robin Spiller, Editor

Vomiting in the recently anticoagulated patient

Clinical presentation

A 42 year old previously healthy man presented with an eight hour history of retrosternal tightness. While clinical examination was unremarkable, his cardiac enzymes were raised and his electrocardiogram showed ST segment elevation in leads II, III, and aVf. He was diagnosed with an acute inferior myocardial infarction and received 1.5 million units of streptokinase over the next hour. His pain settled and he was comfortable overnight.

The following morning he developed epigastric pain and tenderness and vomited twice. His haemoglobin level dropped to 12 g/dl (15 g/dl on admission). Although overall he improved over the next 48 hours, he continued to vomit even though fasting. An upper gastrointestinal endoscopy was performed and demonstrated the duodenal abnormality shown in fig 1.

Question

What is the abnormality shown (fig 1) and what is the most appropriate course of subsequent treatment?

See page 102 for answer

This case is submitted by:

R A Cahill, S Siddique, J O'Connor

Department of General Surgery, Waterford Regional Hospital, Waterford, Ireland

Correspondence to: Mr R Cahill, Department of General Surgery, Waterford Regional Hospital, Waterford, Ireland; rcahill@rcsi.ie

doi: 10.1136/gut.2004.040071




Figure 1 Upper gastrointestinal endoscopy.